Experience of successful laparoscopic sleeve resection of the stomach and treatment of morbid obesity in a patient with a classic form of congenital adrenal dysfunction

The article presents a clinical observation of a patient with congenital adrenal dysfunction (CHD), a salt-losing form of 21-hydroxylase enzyme deficiency (homozygous mutation I 172N), and also with morbid obesity, due to long-term use of high doses of glucocorticosteroids, who underwent bariatric surgery — laparoscopic sleeve resection of the stomach. A feature of the presented case is the elimination of one of the causes of decompensation of the disease, namely, overweight, as well as insulin resistance, which requires the intake of large doses of glucocorticoids, which in turn leads to a worsening of the course of obesity, thereby causing a vicious circle. 7 months after surgical treatment, the goal was achieved — a reduction in the dose of Prednisolone by 25%, with a decrease in body weight by 72.1% of overweight.

The presented case clearly demonstrates the possibility of performing bariatric surgery for the treatment of morbid obesity in patients with CAH with the participation and control of a specialized multidisciplinary team. If there are indications for bariatric intervention, VDKN should not be an absolute contraindication to such operations, and the ratio of the safety profile and the efficacy profile testifies in favor of the need for their implementation.

1. Mokrysheva NG, Melnichenko GA, Adamyan LV, et al. Russian clinical practice guidelines «congenital adrenal hyperplasia». Obesity and metabolism. 2021;18(3):345-382. (In Russ.). doi: https://doi.org/10.14341/omet12787

2. Kareva MA. Vrozhdennaja disfunkcija kory nadpochechnikov u detej: jepidemiologija, geneticheskaja osnova, personalizirovannyj podhod k diagnostike i lecheniju, monitoring somaticheskogo i reproduktivnogo zdorov’ja [dissertation]. Moscow; 2019. (In Russ.).

3. Melnichenko GA, Troshina EA, Molashenko NV, et al. Russian Association of Endocrinologists clinical practice guidelines for diagnosis, treatment and preventive measures in congenital adrenal hyperplasia due to 21-hydroxylase deficiency patients in adulthood. Consilium Medicum. 2016;18(4):8-19. (In Russ.). doi: https://doi.org/10.26442/2075-1753_2016.4.8-19

4. Kareva MA, Chugunov IS. Federal clinical practice guidelines on the management of the patients presenting with congenital adrenal hyperplasia. Problems of Endocrinology. 2014;60(2):42-50. (In Russ.). doi: https://doi.org/10.14341/probl201460242-50

5. Kareva MA, Chugunov IS. Corrigendum to: “Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab. 2021;106(7):e2853-e2853. doi: https://doi.org/10.1210/clinem/dgab316

6. Kunaeva OV, Zernova LJu, Kovalenko TV, et al. Itogi i perspektivy neonatal’nogo skrininga vrozhdennoj disfunkcii kory nadpochechnikov: regional’nye aspekty. Lechenie i profilaktika. 2014;9(1):10-15. (In Russ.).

7. Arlt W, Willis DS, Wild SH, et al. Health Status of Adults with Congenital Adrenal Hyperplasia: A Cohort Study of 203 Patients. J Clin Endocrinol Metab. 2010;95(11):5110-5121. doi: https://doi.org/10.1210/jc.2010-0917

8. Sazonova AI, Troshina EA, Molashenko NV. Metabolic disorders in the adult patients presenting with congenital adrenal hyperpl. Problems of Endocrinology. 2012;58(5):3-9. (In Russ.). doi: https://doi.org/10.14341/probl20125853-9

9. Dedov II, Shestakova MV, Melnichenko GA, et al. Interdisciplinary clinical practice guidelines “Management of obesity and its comorbidities.” Obesity and metabolism. 2021;18(1):5-99. (In Russ.). doi: https://doi.org/10.14341/omet12714

10. Mallappa A, Nella AA, Kumar P, et al. Alterations in hydrocortisone pharmacokinetics in a patient with congenital adrenal hyperplasia following bariatric surgery. J Endocr Soc. 2017;1(7):994-1001. doi: https://doi.org/10.1210/js.2017-00215

11. Ahmed A, Rabbitt E, Brady T, et al. A switch in hepatic cortisol metabolism across the spectrum of non-alcoholic fatty liver disease. PLoS One. 2012;7(2):e29531 doi: https://doi.org/10.1371/journal.pone.0029531